Know Cancer

forgot password

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma

Phase 2
18 Years
Open (Enrolling)
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma

Thank you

Trial Information

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma


I. To evaluate in a Phase II study a preliminary estimate of the complete response (CR) rate
of a new chemotherapy regimen involving Cyclophosphamide, Etoposide, Vincristine and
Prednisone (CEOP) alternating with Pralatrexate (P) as front line therapy for patients with
Stage II, III and IV Peripheral T-Cell NHL not otherwise specified (NOS), Anaplastic large
cell lymphoma (ALK negative), Angioimmunoblastic T-cell lymphoma, Enteropathy associated
T-cell lymphoma, Hepatosplenic gamma delta T-cell lymphoma followed by an optional stem cell
transplant with high dose chemotherapy and Autologous stem cell transplant.


I. To evaluate partial response (PR). II. To evaluate overall response (CR+PR). III. To
evaluate the safety and tolerability of the regimen. IV. To assess the 2 year event free
survival (EFS) and overall survival (OS) using this regimen.

V. To assess the percentage of patients who intended to receive transplant versus those who
actually proceeded with transplant.

VI. To evaluate the ability to collect peripheral blood stem cells after this regimen.


Patients receive cyclophosphamide intravenously (IV) and vincristine sulfate IV on day 1,
etoposide IV on days 1-3 or orally (PO) once daily (QD) on days 2-3, and prednisone PO QD on
days 1-5 (CEOP administration). Patients also receive pralatrexate IV over 3-5 minutes on
days 15, 22, and 29 (P administration). Treatment repeats every 42 days for up to 6 courses
in the absence of disease progression or unacceptable toxicity.

Patients with CR or PR, per investigators discretion, may then undergo hematopoietic stem
cell collection and administration of standard preparative regimen followed by hematopoietic
stem cell transplantation.

After completion of study treatment, patients are followed up for 2 years (transplant
patients) or periodically.

Inclusion Criteria:

- Histologically confirmed new diagnosis of Stage II, III and IV peripheral T-cell NHL
not otherwise specified (NOS), anaplastic large cell lymphoma (ALK negative) (ALK
positive if international prognostic index [IPI] 3, 4, or 5), angioimmunoblastic
T-cell lymphoma, enteropathy associated T-cell lymphoma, hepatosplenic gamma delta
T-cell lymphoma

- Pathology material (hematoxylin and eosin [H&E] stain, immunohistochemistry [IHC] and
pathology report from initial diagnosis, if slides are not available, then 8
unstained slides of 4 micron thickness or a representative block should be sent) will
be reviewed, and the diagnosis confirmed by University Nebraska Medical Center (UNMC)
pathology department (retrospective diagnostic review: treatment may commence prior
to the UNMC review)

- No prior therapy with the exception of prior radiation therapy and 1 cycle of
chemotherapy based on current diagnosis and clinical condition

- Age 19 years or older (the age of consent in Nebraska); age 18 years or older
(applicable to states where the age of majority is 18)

- Expected survival duration of >= six months

- Karnofsky Performance Status >= 70

- Absolute neutrophil count (ANC) >= 1000 cells/mm^3, unless due to lymphoma
involvement of the bone marrow

- Platelet Count >= 100 mm^3, unless due to lymphoma involvement of the bone marrow

- Total bilirubin =< 1.5 x upper normal limit (ULN), or =< 3 x ULN if documented
hepatic involvement with lymphoma, or =< 5 x ULN if history of Gilbert's Disease

- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=<
5 x ULN if documented hepatic involvement with lymphoma)

- Serum potassium within normal range

- Serum creatinine < 2.0 mg/dL or calculated creatinine clearance (CrCl) > 45 mL/min

- Prothrombin time (PT) or international normalized ratio (INR), and partial
thromboplastin time (PTT) =< 1.5 x ULN unless patient is receiving anticoagulants; if
patient is on anticoagulation therapy, levels should be within therapeutic range

- Patients with measurable disease; patients with non-measurable but evaluable disease
may be eligible after discussion with the principal investigator (PI); baseline
measurements and evaluations must be obtained within 6 weeks of registration to the
study; abnormal positron emission tomography (PET) scans will not constitute
evaluable disease, unless verified by computed tomography (CT) scan or other
appropriate imaging

- Patients with measurable disease must have at least one objective measurable disease
parameter; a clearly defined, bidimensionally measurable defect or mass measuring at
least 2 cm in diameter on a CT scan will constitute measurable disease; proof of
lymphoma in the liver is required by a confirmation biopsy

- Women must not be pregnant or breast-feeding due to teratogenic effects of

- All females of childbearing potential must have a blood test within 2 weeks
prior to registration to rule out pregnancy

- Pregnancy testing is not required for post-menopausal or surgically sterilized

- Male and female patients of reproductive potential must agree follow accepted birth
control measures

- Patient must be able to adhere to the study visit schedule and other protocol

- Patients must be willing to give written informed consent, and sign an
institutionally approved consent form before performance of any study-related
procedure not part of normal medical care; with the exception of 1 cycle of
chemotherapy based on current diagnosis and clinical condition, with the
understanding that consent may be withdrawn by the subject at any time without
prejudice to future medical care

- No serious disease or condition that, in the opinion of the investigator, would
compromise the patient's ability to participate in the study

Exclusion Criteria:

- Pregnant or breast feeding females

- Known positive for human immunodeficiency virus (HIV), human T-lymphotropic virus
type 1 (HTLV-1), or infectious hepatitis, type A, B or C or active hepatitis

- Major surgery within 2 weeks of study drug administration

- Prior malignancies within the past 3 years with exception of adequately treated basal
cell, squamous cell skin cancer, or thyroid cancer; carcinoma in situ of the cervix
or breast; prostate cancer of Gleason Grade 6 or less with stable prostate-specific
antigen (PSA) levels

- Patients with a diagnosis of other peripheral T-cell lymphoma (PTCL) histologies
other than those specified in the inclusion criteria

- Contraindication to any of the required concomitant drugs or supportive treatments,
including hypersensitivity to all anticoagulation and antiplatelet options, antiviral
drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

- Any other clinically significant medical disease or condition laboratory abnormality
or psychiatric illness that, in the Investigator's opinion, may interfere with
protocol adherence or a subject's ability to give informed consent

- Concomitant administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and
trimethoprim/sulfamethoxazole will not be allowed, since these may result in delayed
clearance of pralatrexate

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

CR rate of CEOP and P treatment

Outcome Description:

Every patient who fulfills all aspects of patient eligibility who receives at least 2 complete course of chemotherapy will be evaluable for the response endpoint. Response rates will be descriptively summarized using percentages and 95% confidence intervals. A CR rate > 50% would be promising if the toxicity profile is acceptable.

Outcome Time Frame:

Up to 6 courses

Safety Issue:


Principal Investigator

Julie Vose

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Nebraska


United States: Food and Drug Administration

Study ID:




Start Date:

July 2011

Completion Date:

Related Keywords:

  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-cell Lymphoma
  • Hepatosplenic T-cell Lymphoma
  • Peripheral T-cell Lymphoma
  • Immunoblastic Lymphadenopathy
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral
  • Lymphoma, Large-Cell, Anaplastic



Mayo ClinicRochester, Minnesota  55905
Stanford UniversityStanford, California  94305
Emory University School of MedicineAtlanta, Georgia  30322
UNMC Eppley Cancer Center at the University of Nebraska Medical CenterOmaha, Nebraska  68198-7680
Mayo Clinic in ArizonaScottsdale, Arizona  85259-5404
Duke University Medical CenterDurham, North Carolina  27710
University of Massachusetts Medical SchoolWorcester, Massachusetts  01605
University of ChicagoChicago, Illinois  60637
Siteman Cancer Center at Washington UniversitySaint Louis, Missouri  63110